ABSTRACT
OBJECTIVES@#To study the significance of interleukin-6 (IL-6) and interleukin-27 (IL-27) in the differential diagnosis of acute respiratory distress syndrome (ARDS) and neonatal respiratory distress syndrome (NRDS) in preterm infants.@*METHODS@#The preterm infants with the manifestation of respiratory distress who were treated in the Neonatal Diagnosis and Treatment Center, Children's Hospital of Chongqing Medical University, from March to November 2021, were enrolled in this prospective study. According to the diagnosis results, they were divided into two groups: ARDS group (n=18) and NRDS group (n=20). ELISA was used to measure the plasma levels of IL-6 and IL-27. The receiver operating characteristic (ROC) curve was used to analyze the value of each index in the diagnosis of ARDS.@*RESULTS@#The ARDS group had significantly higher plasma levels of IL-6 and IL-27 than the NRDS group (P<0.05). The ROC curve analysis showed that IL-6 had an area under the ROC curve (AUC) of 0.867 for the diagnosis of ARDS, with a sensitivity of 61.1% and a specificity of 95.0% at the cut-off value of 56.21 pg/mL. The ROC curve analysis also showed that IL-27 had an AUC of 0.881 for the diagnosis of ARDS, with a sensitivity of 83.3% and a specificity of 80.0% at the cut-off value of 135.8 pg/mL.@*CONCLUSIONS@#Plasma IL-6 and IL-27 can be used as biological indicators for early differential diagnosis of ARDS and NRDS in preterm infants.
Subject(s)
Humans , Infant, Newborn , Diagnosis, Differential , Infant, Premature , Interleukin-27/blood , Interleukin-6/blood , Pilot Projects , Prognosis , Prospective Studies , ROC Curve , Respiratory Distress Syndrome, Newborn/diagnosis , Respiratory Distress Syndrome, Newborn/diagnosisABSTRACT
Effector CD4[+] T cell subsets play an important role in Multiple Sclerosis [MS]. Interleukin-27 [IL-27] suppresses Th [Th1, Th2 and Th17] cells and dampens autoimmunity and tissue inflammation by promoting the generation of Type 1 regulatory T cells [Tr1]. To identify the relative levels of IL-27 and IL-17A in MS disease. In a case-control study, venous blood was collected from forty MS patients and forty-three healthy subjects as control group. Serum levels of IL-27 and IL- 17A were measured by ELISA method. A significant difference between serum IL-17A concentration in patients [120.68 +/- 209.85 pg/ml] and control group [67.26 +/- 117.76 pg/ml, p=0.016] was found. Serum IL-27 levels of the MS patients [159.7 +/- 581.4 pg/ml] were significantly lower than control subjects [180.35 +/- 507.84 pg/ml, p=0.001]. Our findings show decreased levels of IL-27 against increasing IL-17A levels in patients group which may suggest the suppressive role of IL-27 on inflammatory process of MS